CARA News Alert Cara Therapeutics Inc. (CARA) 9.94 12/13/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cara Therapeutics Inc. (CARA) 9.94 $CARA

Enteris BioPharma's Formulation Technology Enables Oral Delivery of Cara Therapeutics' CR845 Peptide for Acute and Chronic Pain in Phase 1a / 1b Trial
PR Newswire - Tue Dec 09, 7:10AM CST
Enteris BioPharma, Inc., an industry leader in oral peptide delivery, congratulates Cara Therapeutics (Nasdaq: CARA) on the successful completion of the Phase 1a / 1b clinical trial of its peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain. Cara's tablet formulation of CR845 utilizes Enteris' proprietary oral delivery technology.
CARA: 9.94 (-0.06)

Novus Becomes an Insurance Leader as MMJ Market Approaches Tipping Point
ACCESSWIRE - Mon Dec 08, 9:21AM CST
WHITEFISH, MT / ACCESSWIRE / December 8, 2014 / A unique company in the MMJ space today that is focused on the medical insurance side of the business is Novus Acquisition & Development (OTC: NDEV). Novus provides health insurance and insurance related solutions to the growing wellness and MMJ markets using an innovative cost-saving provider network model that is administered via their wholly-owned Novus Medical Group subsidiary's Novus MedPlan. The timely rollout of the Novus MedPlan in states where MMJ is legal, which gives patients access to considerable discounts on MMJ products for a modest subscriber fee of under $20 a month, was recently highlighted in Forbes as the number one pick, taking the top slot out of a list of the eight hottest publicly traded companies to draw the interest of investors in this rapidly emerging sector.
CARA: 9.94 (-0.06), INSY: 41.00 (+1.82), GWPH: 72.41 (+1.18)

Cara Therapeutics (CARA) in Focus: Stock Rises 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 8:46AM CST
Cara Therapeutics (CARA) was a big mover last session, with shares rising just over 6% on the day.
BIIB: 344.49 (+2.16), CARA: 9.94 (-0.06), ANIP: 54.28 (+2.33), AFFX: 8.94 (-0.36)

New Medical Chief at Cara
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 9:29AM CST

CARA: 9.94 (-0.06)

Cara Therapeutics Announces Appointment of Joseph Stauffer, D.O., as Chief Medical Officer
GlobeNewswire - Tue Dec 02, 7:05AM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the appointment of Joseph Stauffer, D.O., as Chief Medical Officer, effective immediately. Dr. Stauffer will oversee the clinical development of Cara's lead compound, CR845, as well as its pipeline of other novel pain therapies.
CARA: 9.94 (-0.06)

Cara Therapeutics Announces Positive Top-Line Results From Phase 1a / 1b Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain
GlobeNewswire - Tue Dec 02, 7:00AM CST
-- All tested tablet strengths pharmacologically active, safe and well tolerated after single and multiple dose administration
CARA: 9.94 (-0.06)

Cara Therapeutics to Webcast Presentation at 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 25, 3:01PM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 26 Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014, at 2:30 p.m. ET in New York City.
CARA: 9.94 (-0.06)

Cara Therapeutics to Webcast Presentation at 2014 Stifel Healthcare Conference
GlobeNewswire - Tue Nov 11, 3:01PM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 2014 Stifel Healthcare Conference on Tuesday, November 18, 2014, at 2:25 p.m. ET in New York City.
CARA: 9.94 (-0.06)

Cara Therapeutics ups revenues 10% in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:59AM CST

CARA: 9.94 (-0.06)

Cara Therapeutics' (CARA) CEO Derek Chalmers on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 7:44PM CST

CARA: 9.94 (-0.06)

Cara Therapeutics misses by $0.07
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:18PM CST

CARA: 9.94 (-0.06)

Cara Therapeutics Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 3:11PM CST
-- Reported positive top-line data from human abuse liability trial for I.V. CR845
CARA: 9.94 (-0.06)

Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST

HK: 2.01 (-0.09), WWD: 48.04 (-1.66), LLNW: 2.86 (+0.01), FXEN: 1.60 (-0.07), RMTI: 8.20 (+0.04), CZR: 12.83 (-2.03), EGY: 4.49 (-0.06), ICUI: 80.95 (-1.04), ICEL: 5.19 (-0.28), SAAS: 8.09 (-0.14), DMD: 6.35 (+0.09), NPSP: 31.28 (-0.99), SCLN: 8.23 (-0.32), ATHX: 1.36 (+0.05), CMLS: 3.87 (+0.03), TC: 1.38 (-0.07), ATW: 27.19 (-0.52), CLUB: 6.22 (+0.01), RAX: 45.39 (-0.86), PTLA: 28.27 (-0.27), IPAR: 26.05 (-0.73), ATLS: 26.31 (-0.13), AMBC: 23.08 (-0.97), CUI: 7.37 (-0.12), PDLI: 7.41 (-0.08), OMER: 22.81 (+0.12), PRAA: 57.23 (-0.17), CARA: 9.94 (-0.06), HALO: 7.99 (-0.16), MODN: 10.50 (+0.05), CALL: 7.70 (-0.05), ASEI: 47.24 (-1.33), HGR: 21.22 (+0.21), ERII: 4.72 (+0.06)

Cara Therapeutics reports November 10
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 3:22PM CST

CARA: 9.94 (-0.06)

Cara Therapeutics to Announce Third Quarter 2014 Financial Results on November 10, 2014
GlobeNewswire - Mon Nov 03, 3:01PM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, November 10, 2014, at 4:30 p.m. ET to report third quarter 2014 financial results and provide a corporate update.
CARA: 9.94 (-0.06)

Cara Therapeutics (CARA) Worth Watching: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:39AM CDT
Cara Therapeutics Inc. (CARA) was a big mover last session, as its shares rose over 6% on the day.
MDVN: 106.86 (-1.16), MACK: 10.64 (+0.42), CARA: 9.94 (-0.06), ILMN: 184.30 (-2.53)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 8:15AM CDT

CAMT: 3.03 (-0.05), ORB: 22.75 (-1.09), UNIS: 2.86 (-0.10), ALLY: 22.19 (-0.45), FB: 77.83 (+0.10), AMCC: 5.87 (+0.03), INVN: 15.18 (-0.29), AKS: 5.20 (-0.13), NBG: 1.79 (-0.01), RFMD: 15.50 (-0.29), BLDP: 1.86 (-0.03), CARA: 9.94 (-0.06), GT: 26.49 (-0.60), HIVE: 4.54 (-0.15), MCGC: 3.66 (+0.08), IBIO: 0.69 (unch), BIOS: 5.91 (-0.12), UBA: 22.08 (-0.31), ARCP: 8.99 (-0.24), SNY: 45.16 (-1.05), STM: 7.34 (-0.15), X: 27.82 (-0.72)

Cara Therapeutics' pain drug positive in human abuse liability trial
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 7:42AM CDT

CARA: 9.94 (-0.06)

Cara Therapeutics Announces Positive Results From Human Abuse Liability Trial of Peripheral Opioid for Acute Pain, I.V. CR845
GlobeNewswire - Wed Oct 29, 6:00AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain without eliciting typical opioid (narcotic) side effects, today announced positive results from its Human Abuse Liability (HAL) trial of an intravenous (I.V.) formulation of CR845, a first-in-class peripherally-selective kappa opioid agonist.
CARA: 9.94 (-0.06)

4 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Oct 29, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
CARA: 9.94 (-0.06), LIOX: 5.50 (-0.07), QRHC: 1.29 (-0.02), TWI: 9.76 (-0.17)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 135

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 35

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 20

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 78

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 29

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 194

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 119

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 117

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 59

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading

Top 5 Most Recently Viewed Articles

Ocuphire Pharma Faces Scrutiny Over Shareholder Obligations

Updated Category News Views 81

Ocuphire Pharma Under Investigation by Ademi LLP Recently, there have been growing concerns regarding the fiduciary responsibilities of Ocuphire Pharma, Inc. (NASDAQ: OCUP) to its public shareholders. Ademi LLP has initiated an investigation focused on whether the company is adequately protecting the interests of its shareholders amidst its dealings with Opus Genetics....

Continue Reading
Investigation Into Shareholder Claims Against AMLX, FIVE, HUM, and VSTS

Updated Category News Views 190

Grabar Law Office Investigates Shareholders' Rights Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), Five Below, Inc. (NASDAQ: FIVE), Humana Inc. (NYSE: HUM), and Vestis Corp. (NYSE: VSTS) shareholders may have claims worth exploring. Grabar Law Office wants to inform these shareholders about the ongoing investigations into potential securities fraud that could have affected...

Continue Reading
Investors Seek Recovery in Class Action Against Paragon 28, Inc.

Updated Category News Views 109

Class Action Lawsuit Filed for Paragon 28, Inc. Investors We are reaching out to inform investors about an important class action securities lawsuit involving Paragon 28, Inc. This initiative aims to recover losses for investors who may have been adversely affected by purported securities fraud associated with the company. Details of the Class Action The class action...

Continue Reading
Alto Ingredients, Inc. Announcement for Q2 2025 Results

Updated Category News Views 165

Alto Ingredients, Inc. to Announce Second Quarter Financial Results Alto Ingredients, Inc. (NASDAQ: ALTO), a prominent producer and distributor of specialty alcohols and renewable fuels, is set to release its financial results for the second quarter of 2025. This announcement will take place after the market closes on Wednesday, August 6, 2025. Conference Call Details...

Continue Reading
Phare Bio Secures $27 Million to Revolutionize Antibiotic Discovery

Updated Category News Views 226

Phare Bio scored big back in 2024 with up to $27 million in funding from the Advanced Research Projects Agency for Health (ARPA-H). This isn’t just pocket change; it’s a lifeline aimed at supercharging their generative artificial intelligence (AI) platform. Teaming up with MIT's Collins Lab and Harvard's Wyss Institute, they set their sights on developing new classes...

Continue Reading